Antibody-drug conjugates - a perfect synergy

Area of Science:

• Biopharmaceuticals
• Oncology
• Drug Development

Background:

• Cancer remains a leading cause of death, highlighting the need for novel therapeutic strategies.
• Antibody-drug conjugates (ADCs) are an emerging class of biopharmaceuticals with the potential to target cancer cells effectively.
• Significant interest from pharmaceutical companies and a growing clinical pipeline underscore the promise of ADCs.

Purpose of the Study:

• To review the progress in the development of antibody-drug conjugates (ADCs) as a new class of cancer therapeutics.
• To examine the antibody and drug components of ADCs, as well as linkage technology and its consequences.
• To present recent developments in ADC design, supported by clinical examples.

Main Methods:

• Separately describing the antibody and drug components of ADCs.
• Examining the technology and consequences of linking antibodies to drugs.
• Analyzing recent advancements in ADC design and clinical applications.

Main Results:

• Antibodies and chemotherapy are being synergistically combined in ADCs.
• Technical challenges in antibody production have been largely overcome.
• Advances in linker technology and the availability of potent drugs are enabling ADC development.

Conclusions:

• ADCs represent a significant advancement in cancer treatment, offering a new therapeutic avenue.
• Understanding the holistic nature of ADCs, including target selection and cellular interactions, is critical.
• Developments in attachment sites and linker chemistry allow for fine-tuning of drug loading, pharmacokinetics, and toxicity.